Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 660 clinical trials
FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)

Patients with metastatic adenocarcinoma of the stomach or the esophagogastric junction (II-III type by Siewert) without previous therapy will be treated with one of two chemotherapy combinations . One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin (FOLFOX6), the others 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Irinotecan (mFOLFIRINOX). Main objective …

cancer
combinations
irinotecan
hepatitis b
leucovorin
  • 0 views
  • 19 Feb, 2024
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.

cancer
solid tumour
peritoneal cancer
hormonal contraception
hair thinning
  • 0 views
  • 19 Feb, 2024
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Moreover, the study will characterize the pharmacokinetic profiles of NIZ985 as a single agent and in combination with Spartalizumab and identify preliminary anti-tumor activity.

  • 0 views
  • 19 Feb, 2024
Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.

The purpose of this project is to realize a randomized open-label study (EudraCT number: 2020-000120-19) to evaluate the safety and the anti-tumor activity of peptide(s)-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck.

cancer
measurable disease
carcinoma in situ of cervix
neutrophil count
cavity
  • 0 views
  • 19 Feb, 2024
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

Chemotherapy-nave patients with EML4-ALK rearrangement and with locally advanced or metastatic non-small cell lung cancer patients will be selected. Patients enrolled in the study will receive brigatinib 90mg for the first 7 days (D 1-7 at cycle 1) and then 180mg daily thereafter for QW4 cycles of duration (28 days …

hepatitis b surface antigen
angina pectoris
blood transfusion
gastrointestinal bleeding
serum bilirubin level
  • 0 views
  • 19 Feb, 2024
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

Stereotactic ablative radiotherapy is an external beam radiation method that delivers large doses of radiation to the cancer in a short period of time, usually 5 treatments. This trial aims to find which of these two approaches is better in terms of patient-reported quality of life.

antiandrogen therapy
bone scan
adenocarcinoma of prostate
stage ii prostate cancer ajcc v8
stage ii prostate cancer
  • 0 views
  • 19 Feb, 2024
Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab

The purpose of the study is to assess the safety, tolerability and preliminary antitumor activity of ZW25 in combination with docetaxel in participants with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and ZW25 in combination with tislelizumab and chemotherapy in participants with HER2-positive gastric/gastroesophageal Junction (GEJ) adenocarcinoma

docetaxel
bispecific antibody
gastric adenocarcinoma
metastatic adenocarcinoma
gastric cancer
  • 0 views
  • 19 Feb, 2024
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma

This is a first-in-human Phase I, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of RO7297089 and make a preliminary assessment of anti-tumor activity in patients with R/R MM for whom no established therapy for MM is appropriate and available or who are intolerant to …

refractory multiple myeloma
measurable disease
multiple myeloma
  • 0 views
  • 19 Feb, 2024
Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.

A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (Part 1), followed by sequential immune targeting with programmed death-ligand (PD-L)1 blockade in combination with low-dose Lenalidomide (Part 2) in patients …

blockade
azacitidine
cancer
antineoplastic
pancreatic ductal adenocarcinoma
  • 0 views
  • 19 Feb, 2024
Neoadjuvant T-VEC in High Risk Early Melanoma

The investigators predict that histologic clearance of the primary tumor in the surgical specimen will be associated with improved RFS. In summary, the goal of this project is to conduct a phase II study to evaluate efficacy of Talimogene laherparepvec in the neoadjuvant setting for primary invasive melanoma in effort …

cancer
advanced melanoma
neutrophil count
hepatitis
aptt
  • 0 views
  • 19 Feb, 2024